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Abstract
Background and aims
The predictive value of traditional risk factors for vascular events in patients with manifest
vascular disease is limited, underscoring the need for novel biomarkers to improve risk strat-
ification. Since hematological parameters are routinely assessed in clinical practice, they
are readily available candidates.
Methods
We used data from 3,922 vascular patients, who participated in the Second Manifestations
of ARTerial Disease (SMART) study. We first investigated associations between recurrent
vascular events and 22 hematological parameters, obtained from the Utrecht Patient Ori-
ented Database (UPOD), and then assessed whether parameters associated with outcome
improved risk prediction.
Results
After adjustment for all SMART risk score (SRS) variables, lymphocyte %, neutrophil count,
neutrophil % and red cell distribution width (RDW) were significantly associated with vascu-
lar events. When individually added to the SRS, lymphocyte % improved prediction of recur-
rent vascular events with a continuous net reclassification improvement (cNRI) of 17.4%
[95% CI: 2.1, 32.1%] and an increase in c-statistic of 0.011 [0.000, 0.022]. The combination
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of lymphocyte % and neutrophil count resulted in a cNRI of 22.2% [3.2, 33.4%] and
improved c-statistic by 0.011 [95% CI: 0.000, 0.022]. Lymphocyte % and RDW yielded a
cNRI of 18.7% [3.3, 31.9%] and improved c-statistic by 0.016 [0.004, 0.028]. However, the
addition of hematological parameters only modestly increased risk estimates for patients
with an event during follow-up.
Conclusions
Several hematological parameters were independently associated with recurrent vascular
events. Lymphocyte % alone and in combination with other parameters enhanced discrimi-
nation and reclassification. However, the incremental value for patients with a recurrent
event was limited.
Introduction
The most common underlying cause of cardiovascular disease is atherosclerosis, leading to
over 13 million deaths per year worldwide [1]. The implementation of preventive therapies
critically depends on the reliable identification of individuals at risk. In clinical practice, vascu-
lar risk assessment is primarily based on risk factors, such as smoking, hypertension, diabetes,
obesity and hyperlipidemia [2]. While a large body of evidence has underpinned the signifi-
cance of such traditional risk factors in primary prevention [3–5], their predictive value for
vascular risk in patients with established vascular disease is less clear [6–8]. Thus, novel risk
factors are needed to improve risk stratification in secondary prevention and to establish the
pathophysiological processes underlying recurrent vascular risk.
The SMART risk score (SRS) has been specifically developed to predict recurrent vascular
events in patients with established atherosclerotic vascular disease [9]. This score not only
includes traditional risk factors, but also vascular disease history, renal function and high-sen-
sitive C-reactive protein (hs-CRP), an inflammatory marker associated with vascular risk [10].
Besides hs-CRP, several other biomarkers have been linked to prognosis of vascular disease,
including N-terminal pro-type brain natriuretic peptide, troponins, ST2 and growth-differen-
tiation factor-15 [6,11]. A recent study identified different routinely-measured hematological
parameters that predict outcomes in patients with coronary artery disease [12]. Because these
parameters are measured by most hematology analyzers, they are readily available for use in
clinical practice without the need to rely on expensive equipment. Despite their potential clini-
cal utility, no study has yet assessed whether hematological parameters improve prediction of
recurrent events beyond established secondary risk factors used in the SRS. Combining data
from the Second Manifestations of ARTerial Disease (SMART) study and the Utrecht Patient
Oriented Database (UPOD), we investigated the incremental value of routinely measured
hematological parameters for the prediction of recurrent vascular events. We first investigated
associations between 22 hematological parameters and recurrent vascular events. Then, we
assessed whether parameters independently associated with recurrent events improved risk
prediction compared to the SRS.
Methods
Study population
We conducted this study in patients with a clinical manifestation of atherosclerotic vascular
disease (cerebrovascular disease, coronary artery disease, peripheral artery disease or
Hematological parameters and recurrent vascular events
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abdominal aortic aneurysm) who participated in the SMART study. Details on disease defini-
tions and recruitment procedures have been published previously [9,13]. Briefly, the SMART
study, an ongoing, single-center, prospective cohort study, enrolled patients aged 18–80 who
were referred to the University Medical Center Utrecht for clinical manifestations of athero-
sclerotic vascular disease or the treatment of vascular risk factors. Because complete hemato-
logical parameters were not available before 2005, we restricted our analysis to a subset of
patients enrolled from January 2005 onwards. For this study, follow-up data were available
until March, 2014. At baseline, patients were requested to fill in a questionnaire on medical
history, symptoms of vascular disease and vascular risk factors. During follow-up, question-
naires were sent to patients or their general practitioner twice a year to obtain information on
their health status. Moreover, hospital discharge letters were collected to verify vascular events.
All events were adjudicated by three members of the Endpoint Committee. The outcome of
interest was a composite endpoint of vascular death, ischemic or hemorrhagic stroke or myo-
cardial infarction, as previously described in more detail [9]. All patients provided written
informed consent. The SMART study was approved by the Ethics Committee of the University
Medical Center Utrecht.
Hematological parameters
We enriched the SMART cohort with 22 routinely measured hematological parameters,
obtained from UPOD, which comprises clinically relevant data from all patients admitted to
the University Medical Center Utrecht, including laboratory measurements. Hematology mea-
surements were performed as part of clinical routine in EDTA blood on the Sapphire hematol-
ogy analyzers (Abbott, Santa Clara, CA). It uses the multi-angle polarized scatter separation
technique. Further details on the quantification of hematological parameters in UPOD have
recently been published elsewhere [12].
Clinical chemistry
Clinical chemistry measurements, i.e. creatinine, total cholesterol, triglycerides, HDL-choles-
terol and hs-CRP, were performed in Li-heparin plasma on clinical routine IVD analyzers
(AU5800, Beckman Coulter, Brea, CA) at the central diagnostic laboratory of the UMC
Utrecht according to international standards (ISO9001, ISO15189). LDL-cholesterol was cal-
culated using the Friedewald equation; eGFR was calculated from creatinine levels according
to the MDRD formula.
Statistical analysis
As for the derivation of the SRS, we truncated all continuous variables, including all hemato-
logical parameters, at the 1st and the 99th percentile to reduce the impact of outliers [9]. Using
single imputation by additive regression, we imputed missing values for all variables included
in the SRS (total n = 126; 0.2%). The variable with the highest percentage of missing values was
hs-CRP (n = 75; 1.9%). To facilitate comparison between different hematological parameters,
all values were scaled to SD units prior to analysis.
We first evaluated associations between each of the 22 hematological parameters and recur-
rent vascular events, using Cox proportional hazards modeling adjusted for all SRS variables
[age, sex, diabetes mellitus, current smoking, systolic blood pressure, total cholesterol, high-
density lipoprotein (HDL) cholesterol, hs-CRP, estimated glomerular filtration rate (eGFR),
years since first vascular event, history of cerebrovascular disease, history of coronary artery
disease, history of abdominal aortic aneurysm, history of peripheral artery disease]. Analogous
to the SRS, hs-CRP was loge-transformed and quadratic terms were added for age and eGFR
Hematological parameters and recurrent vascular events
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[9]. Since none of hematological parameters showed a skewness >2, loge-transformation was
not applied. Hematological parameters were entered as quadratic polynomials if the addition
of a quadratic term improved model fit, as indicated by the likelihood ratio test (p<0.05).
Accordingly, we added a quadratic term for hematocrit. The proportional hazards assumption
was tested for each model using scaled Schoenfeld residuals. Associations between hematologi-
cal parameters and outcome were adjusted for multiple testing. Since several of the 22 parame-
ters were highly correlated (Figure A in S1 File), we estimated the effective number of
independent tests for multiple testing correction using principal component analysis. The first
11 principal components explained over 95% of the variance in the hematology data, yielding
a significance threshold of 0.05/11 = 0.0045.
We next evaluated the added predictive value of hematological parameters, significantly
associated with outcome, by comparing different biomarker models to a reference model in
terms of discrimination and reclassification. The reference model was constructed by fitting
the SRS variables to our dataset. The single biomarker models included the SRS variables and
one of the hematological parameters significantly associated with recurrent event risk. We
additionally assessed the performance of multi-biomarker models that included combinations
of hematological parameters. To evaluate discrimination, we calculated Harrell’s c for each
model and compared c-statistics between each biomarker model and the reference model,
using the jackknife approach proposed by Antolini et al [14]. Extending the area under the
receiver operating characteristic (ROC) curve to censored outcomes, Harrell’s c measures the
ability of a risk prediction model to discriminate individuals with a target events from event-
free individuals. Reclassification was assessed by continuous net reclassification improvement
(cNRI), as implemented in the nricens R package (https://cran.r-project.org/web/packages/
nricens/index.html), which computes NRI for censored survival data. Confidence intervals for
NRI were computed by bootstrapping. To obtain robust reclassification indices, we assessed
cNRI at 7 years, given a median follow-up of 4.6 years (IQR: 2.5–6.9 years). 7 years also corre-
sponds to the follow-up period for which the SRS was initially calibrated before risk estimates
were extrapolated to 10-year risk predictions [9]. Due to the absence of established categories
for the 7-year risk of recurrent vascular events, we did not assess categorical NRI.
Results
3,922 patients with manifest vascular disease enrolled in the SMART cohort were included in
this study. Baseline characteristics of the study population are summarized in Table 1. During
a median follow-up of 4.6 years (IQR: 2.5–6.9 years), 310 recurrent vascular events occurred.
In contrast to Dorresteijn et al. [9], we only included patients recruited from 2005 onwards.
Compared to this study, we observed lower event rates (1.7% vs. 2.6%), most likely reflecting
improved secondary prevention therapies. In line with this, the proportion of patients treated
with statins was higher in our study. Table 2 shows baseline values of all 22 hematological
parameters stratified by event status.
First, we studied associations between hematological parameters and secondary vascular
outcomes. Table A in S1 File displays unadjusted and adjusted hazard ratios (HRs) for all
hematological parameters. HRs for all SRS variables (reference model) are shown in Table B in
S1 File. Since most hematological parameters are directly or indirectly related to immunologi-
cal processes, we assessed whether these associations were independent of hs-CRP. The addi-
tion of hs-CRP particularly attenuated effect estimates for white blood cell count, neutrophil
count, monocyte count and neutrophil % (Fig B in S1 File). Four parameters remained signifi-
cantly associated with vascular events after adjustment for the SRS variables (Fig 1). Lympho-
cyte % showed a negative association with the recurrent vascular events (HR in SD units: 0.80
Hematological parameters and recurrent vascular events
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[95% CI: 0.71, 0.91]), whereas neutrophil count (HR in SD units: 1.19 [1.06, 1.33]), neutrophil
% (HR in SD units: 1.22 [1.08, 1.37]), and RDW (HR in SD units: 1.16 [1.05, 1.28]) were posi-
tively associated with recurrent vascular events.
To assess discrimination and continuous reclassification, we next added each of the four
hematological parameters that were independently associated with recurrent event risk to a
reference model composed of the SRS variables (Table 3). We observed the largest cNRI for
lymphocyte %. For events, this parameter improved continuous reclassification by 13.6%, for
non-events by 3.8%, yielding a cNRI of 17.4% [95% CI: 2.1, 32.1%]. Additionally, lymphocyte
% improved discrimination (c-statistic) by 0.0110 [95% CI: 0.0004, 0.0216]. We also tested
whether lymphocyte % combined with other parameters further improved the predictive per-
formance of the SRS. Neutrophil % was not included into a multi-biomarker model because
this parameter was highly correlated with lymphocyte % (r = -0.92). Lymphocyte % and neu-
trophil count improved cNRI by 22.2% [3.2, 33.4%]. The increase in c-statistic was 0.0112
[0.0004, 0.220], which was comparable to that achieved by lymphocyte % alone. For lympho-
cyte % and RDW combined, the cNRI was 18.7% [3.3, 31.9%], the improvement in c-statistic
Table 1. Baseline characteristics.
All
(N = 3922)
No vascular
event (N = 3612)
Vascular
event (N = 310)
Age, years 61 (54–68) 61 (54–67) 64 (56–71)
Male sex 2850 (73) 2610 (72) 240 (77)
Type of vascular disease
Cerebrovascular disease 1125 (29) 1032 (29) 93 (30)
Coronary artery disease 2588 (66) 2373 (66) 215 (69)
Peripheral artery disease 531 (14) 481 (13) 50 (16)
Abdominal aortic aneurysm 236 (6) 213 (6) 23 (7)
Years since first vascular event
less than 1 year 2283 (60) 2140 (61) 143 (48)
1–2 years 389 (10) 363 (10) 26 (9)
over 2 years 1110 (29) 980 (28) 130 (44)
Current smoking 1060 (27) 954 (27) 106 (34)
Diabetes mellitus 704 (18) 628 (17) 76 (25)
Systolic blood pressure, mm Hg 136 (124–149) 135 (124–149) 140 (129–155)
Diastolic blood pressure, mm Hg 80 (73–88) 80 (74–88) 81 (73–90)
eGFR, ml/min/1.73 m2 77 (66–88) 77 (67–88) 70 (60–84)
Total cholesterol, mmol/l 4.3 (3.7–5.1) 4.3 (3.7–5.1) 4.3 (3.7–5.1)
LDL cholesterol, mmol/l 2.4 (1.9–3.0) 2.4 (1.9–3.0) 2.4 (1.9–3.1)
HDL cholesterol, mmol/l 1.2 (1.0–1.4) 1.2 (1.0–1.4) 1.1 (1.0–1.4)
Triglycerides, mmol/l 1.2 (0.9–1.8) 1.2 (0.9–1.8) 1.3 (0.9–1.9)
hs-CRP, nmol/l 16 (8–36) 15 (8–34) 26 (12–62)
Medication
Lipid-lowering drugs 3140 (80) 2888 (80) 252 (81)
Blood pressure-lowering drugs 3086 (79) 2829 (78) 257 (83)
Glucose-lowering drugs 560 (14) 497 (14) 63 (20)
Antithrombotic drugs 3493 (89) 3206 (89) 287 (93)
Discrete variables are expressed as count (%), continuous variables as median (IQR). Type of vascular disease is not mutually exclusive as patients may have experienced
several manifestations of vascular disease. eGFR: estimated glomerular filtration rate (see [9]); HDL: high-density lipoprotein; hs-CRP: high-sensitivity C-reactive
protein; IQR: inter-quartile range; LDL: low-density lipoprotein.
https://doi.org/10.1371/journal.pone.0202682.t001
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was 0.016 [0.004, 0.028]. With a cNRI of 17.2% [4.1, 32.8%], all three parameters yielded a
lower reclassification improvement than the combination of lymphocyte % and neutrophil
count. Lymphocyte % in combination with RDW improved discrimination with an increase in
c-statistic of 0.016 [0.004, 0.028]. Fig 2 illustrates the change in predicted risk for different bio-
marker models, stratified by event status. While lymphocyte % alone and the combination of
lymphocyte % and neutrophil count showed the largest continuous reclassification improve-
ment (Table 3) for events, risk estimates increased only modestly in patients who experienced
an event. Lymphocyte % and RDW combined predominantly increased risk estimates for
events in the higher risk range.
Discussion
In this study, we evaluated the incremental predictive value of routinely measured hematological
parameters for the prediction of recurrent vascular events in patients with established vascular dis-
ease. We first investigated associations between 22 parameters and recurrent event risk and then
assessed whether parameters associated with outcome improved risk prediction. Out of the four
parameters significantly associated with outcome, lymphocyte % showed the largest cNRI when
individually added to the SRS. Overall, the combination of lymphocyte % and neutrophil count
yielded the largest cNRI compared to the SRS, but only modestly improved discrimination (c-sta-
tistic) and risk estimates for patients who experienced an event during follow-up.
Table 2. Hematological parameters.
Unit No vascular event Vascular event
White blood cells 109/l 6.6 (5.5–7.9) 7.2 (5.9–8.7)
Neutrophils 109/l 3.8 (3.0–4.7) 4.2 (3.5–5.4)
Lymphocytes 109/l 1.9 (1.5–2.4) 1.9 (1.5–2.3)
Monocytes 109/l 0.54 (0.44–0.67) 0.58 (0.49–0.70)
Eosinophils 109/l 0.19 (0.12–0.28) 0.21 (0.15–0.28)
Basophils 109/l 0.04 (0.02–0.06) 0.04 (0.03–0.06)
Neutrophil % % 57.9 (52.1–63.7) 60.3 (55.1–66.2)
Lymphocyte % % 29.4 (24.4–34.7) 26.2 (21.8–32.0)
Monocyte % % 8.2 (6.9–9.7) 8.2 (6.8–9.8)
Eosinophil % % 2.9 (1.9–4.2) 3.0 (2.1–4.1)
Basophil % % 0.61 (0.39–0.88) 0.58 (0.36–0.78)
Red blood cells 1012/l 4.7 (4.4–5.0) 4.6 (4.2–4.9)
Hemoglobin mmol/l 8.8 (8.3–9.3) 8.8 (8.2–9.3)
MCV fl 89.8 (87.1–92.5) 89.9 (86.9–92.8)
RDW % 12.1 (11.7–12.7) 12.3 (11.8–13.3)
MCH fmol 1.9 (1.8–2.0) 1.9 (1.8–2.0)
MCHC mmol/l 21.1 (20.7–21.5) 21.1 (20.5–21.5)
Hematocrit % 41.7 (39.3–44.1) 41.7 (38.6–44.4)
Platelets 109/l 237 (202–280) 235 (203–276)
MPV fl 7.7 (7.2–8.4) 7.9 (7.3–8.6)
Plateletcrit % 0.19 (0.17–0.22) 0.20 (0.17–0.23)
PDW 10xGSD 16.1 (15.8–16.6) 16.2 (15.8–16.6)
Values are expressed as median (IQR) and stratified by event status. GSD: geometric standard deviation; IQR: inter-quartile range; MCH: mean corpuscular
hemoglobin; MCHC: mean corpuscular hemoglobin concentration; MCV: mean corpuscular volume; MPV: mean platelet volume; PDW: platelet distribution width;
RDW: red cell distribution width.
https://doi.org/10.1371/journal.pone.0202682.t002
Hematological parameters and recurrent vascular events
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Lymphocytes have been implicated in the modulation of inflammatory processes at distinct
stages of atherogenesis [15]. Numerous observational studies in patients with coronary artery
disease have reported associations of low absolute and relative lymphocyte levels with poor
Fig 1. Each of the 22 hematological parameters was analyzed separately. HRs are given per SD-unit increase adjusted for all SRS variables. CI:
confidence interval; HR: hazard ratio; MCH: mean corpuscular hemoglobin; MCHC: mean corpuscular hemoglobin concentration; MCV: mean
corpuscular volume; MPV: mean platelet volume; PDW: platelet distribution width; RDW: red cell distribution width; SD: standard deviation;
SRS: SMART risk score. A quadratic term was added for hematocrit. Significance test for quadratic polynomial after adjustment for all SRS
variables: χ2(df = 2) = 6.2; p = 0.045.
https://doi.org/10.1371/journal.pone.0202682.g001
Table 3. Predictive performance of hematological parameters.
Reclassification improvement %
Change in c-statistic [95% CI] with
event
without
event
Net
[95% CI]
Neutrophils 0.006 [-0.002, 0.014] -9.1 15.6 6.5 [-6.0, 22.7]
Neutrophil % 0.008 [-0.002, 0.018] 7.2 6.7 13.9 [-0.3, 27.7]
Lymphocyte % 0.011 [0.000, 0.022] 13.6 3.8 17.4 [2.1, 32.1]
RDW 0.007 [-0.001, 0.015] -11.3 25.0 13.6 [-1.9, 26.4]
Lymphocyte % +
neutrophils
0.011 [0.000, 0.022] 14.8 7.4 22.2 [3.2, 33.4]
Lymphocyte % +
RDW
0.016 [0.004, 0.028] 9.0 9.7 18.7 [3.3, 31.9]
Lymphocyte % +
neutrophils + RDW
0.016 [0.004, 0.028] 5.1 12.0 17.2 [4.1, 32.8]
First, hematological parameters significantly associated with outcome were individually added to a reference model composed of the SRS variables. For each single
biomarker model (SRS + hematological parameter), we evaluated improvement in discrimination (c-statistic) and reclassification (NRI) compared to the reference
model (SRS). We then assessed the predictive performance of multi-biomarker models comprising combinations of lymphocyte % and other hematological parameters.
NRI: net reclassification improvement; RDW: red cell distribution width; SRS: SMART risk score.
https://doi.org/10.1371/journal.pone.0202682.t003
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cardiovascular outcomes [12,16–21]. However, some studies found no link between absolute
lymphocyte count and all-cause mortality in pre-existing coronary artery disease [22–24].
Consistent with a role of low lymphocyte levels in vascular disease progression, lymphocyte
apoptosis is enhanced in myocardial infarction, but not in stable angina, indicating that low
lymphocyte levels may specifically reflect inflammatory processes in advanced atherosclerosis
(e.g. plaque rupture) [25]. In our study, however, lymphocyte % rather than absolute lympho-
cyte count was associated with recurrent vascular events. Accordingly, lymphocyte levels were
Fig 2. Predicted 7-year risks for reference model (SRS) vs. selected biomarker models (SRS + hematological parameters) stratified by event
status. Patients who did not experience a recurrent vascular event during 7-years of follow up (gray circles) were correctly reclassified if there
predicted risk was lower after the addition of hematological parameters to the SRS (below the black line). Patients who experienced an event (black
squares) were correctly reclassified if there predicted risk was higher after the addition of hematological parameters to the SRS (above the black line).
RDW: red cell distribution width; SRS: SMART risk score.
https://doi.org/10.1371/journal.pone.0202682.g002
Hematological parameters and recurrent vascular events
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comparable between patients with and without a recurrent event during follow-up–unlike
concentrations of other white blood cell types, such as neutrophils and monocytes (Table 2).
Low lymphocyte % may thus reflect increased levels of other white blood cell types in patients
at risk.
Besides lymphocyte %, both absolute and relative neutrophil count were independently
associated with recurrent vascular risk without improving risk prediction when individually
added to the SRS. The combination of lymphocyte % and absolute neutrophil count showed
the largest cNRI of all models assessed, but only moderately increased risk estimates for events.
The discrimination improvement with lymphocyte % and absolute neutrophil count was like-
wise limited with an increase in c-statistic equal to that achieved by lymphocyte % alone. The
neutrophil to lymphocyte ratio has been widely studied as a marker of cardiovascular risk, sug-
gesting that neutrophil levels are associated with poor prognosis of coronary and peripheral
artery disease [26]. There is mounting evidence that neutrophils play an important role in
early and advanced atherosclerosis by exacerbating endothelial dysfunction, recruiting mono-
cytes to atherosclerotic lesions, promoting foam cell formation and by destabilizing atheroscle-
rotic plaques [27].
RDW was also independently associated with clinical outcome. Several studies have linked
increased RDW to poor outcomes in patients with coronary artery disease, stroke or peripheral
artery disease [12,28–31]. RDW is a measure of the variation in erythrocyte volume. The
mechanisms by which RDW relates to cardiovascular risk are unknown. Severe inflammation
is associated with inhibition of erythrocyte maturation, which results in anisocytosis, suggest-
ing that RDW reflects enhanced inflammation in atherosclerosis, potentially relevant to dis-
ease progression [32]. However, RDW did not improve risk prediction and, when combined
with lymphocyte %, yielded a cNRI comparable to that achieved by lymphocyte % alone.
Moreover, RDW and lymphocyte % predominantly increased risk estimates for events in the
higher risk range. Since patients with a high SRS would already be eligible for increased sur-
veillance and more extensive treatment, the added value of RDW for clinical risk prediction is
limited.
In the unadjusted analysis, total white blood cell count and monocyte count were strongly
associated with recurrent events. However, adjustment for all SRS variables attenuated effect
estimates for both parameters, especially due to the inflammatory marker hs-CRP (Fig B in S1
File). In vitro findings suggest that CRP interacts with monocytes to enhance inflammation in
acute coronary syndrome [33]. Thus, hs-CRP and monocytes may share a common patho-
physiological pathway, whereas other hematological parameters may reflect inflammatory pro-
cesses that do not, or to a lesser extent, involve CRP. Overall, our findings lend further support
to the inflammatory hypothesis of atherothrombosis and add to recent clinical trial data sug-
gesting that anti-inflammatory therapy reduces cardiovascular risk in secondary prevention
[34].
Hematological parameters are routinely measured in many hospitals and do not require
expensive equipment for analysis, underscoring their clinical potential. In our study, lympho-
cyte % alone and combined with other hematological parameters yielded the largest cNRI.
However, these models only marginally improved discrimination and absolute risk estimates
for events. Thus, it remains to be determined whether the incorporation of hematological
parameters into risk prediction algorithms would influence clinical decision making in sec-
ondary prevention. Since many clinical and demographic characteristics are not assessed sys-
tematically in clinical routine, it is often not possible to calculate clinical scores, such as the
SRS. Routine hematology testing may be combined with other emerging biomarker technolo-
gies suitable for clinical laboratory use to construct biomarker risk scores that do not depend
on the availability of clinical information. Such biomarker-based scores could routinely be
Hematological parameters and recurrent vascular events
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computed by clinical chemistry laboratories, facilitating the implementation of risk assessment
tools for secondary prevention in clinical practice. Besides adding hematological parameters to
established clinical scores, future studies also evaluate their predictive value in combination
with other biomarkers.
Moreover, the ability of hematological parameters to predict recurrent vascular risk may
vary between different manifestations of vascular disease, such as myocardial infarction and
ischemic stroke. Since hematological parameters were not available from all SMART patients,
the sample size of our study population was limited. As a result, we could not perform strati-
fied analyses for different vascular disease groups. Therefore, further research is required to
corroborate our findings in larger cohorts and establish the predictive value of hematological
parameters for different manifestations of vascular disease.
In conclusion, we identified several hematological parameters that were independently
associated recurrent vascular event in patients with vascular disease. When added to a model
comprising the SRS variables, lymphocyte % alone and in combination with other hematologi-
cal parameters, especially with neutrophil count, improved risk prediction, but only modestly
increased risk estimates for patients who experienced a recurrent vascular event.
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